SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs informs about company updates

05 Sep 2019 Evaluate

Laurus Labs has informed that it has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019. And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF funded projects. Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy). A press release to this extent is enclosed.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs Share Price

1176.55 12.55 (1.08%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×